Monday, July 23, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Healthcare Trust of America, Inc. Sets Dates to Report 2018 Second Quarter Financial Results and Host Conference Call
 
(July 11, 2018)

SCOTTSDALE, Ariz., July 11, 2018 /PRNewswire/ -- Healthcare Trust of America, Inc. (NYSE: HTA), the largest dedicated owner and operator of medical office buildings in the United States, announced today that on Thursday, August 2, 2018, after the market closes, HTA will report its financial results for the three months ending June 30, 2018.

Healthcare Trust of America, Inc. Logo. (PRNewsFoto/Healthcare Trust of America, Inc.)

The Company plans to host a conference call and webcast on Friday, August 3, 2018 at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) to review its financial performance and operating results for the three months ending June 30, 2018.



Conference Call and Webcast:
Domestic: (877) 507-6265 / International: (412) 902-6633 / Canada: (855) 669-9657
Webcast: www.htareit.com under the Investor Relations tab

Replay:
Domestic: (877) 344-7529 / International: (412) 317-0088 / Canada: (855) 669-9658
Conference ID: 10122321
Available August 3, 2018 (one hour after the end of the conference call) to September 3, 2018 at 12:00 PM Eastern Time (9:00 a.m. Pacific Time)

About Healthcare Trust of America, Inc. (NYSE: HTA)
Healthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of medical office buildings in the United States, comprising over 24 million square feet of GLA, with over $7 billion invested primarily in medical office buildings. HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations. Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions which translates to superior demographics, high-quality graduates, intellectual talent and job growth. The strategic markets HTA invests in support a strong, long-term demand for quality medical office space. HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market. This drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation. Headquartered in Scottsdale, Arizona, HTA has developed a national brand with dedicated relationships at the local level. Founded in 2006 and listed on the New York Stock Exchange in 2012, HTA has produced attractive returns for its stockholders that have significantly outperformed the S&P 500 and US REIT indices. More information about HTA can be found on the Company's Website, Facebook, LinkedIn and Twitter.

Forward-Looking Language
This press release contains certain forward-looking statements. Forward-looking statements are based on current expectations, plans, estimates, assumptions and beliefs, including expectations, plans, estimates, assumptions and beliefs about HTA, stockholder value and earnings growth.

The forward-looking statements included in this press release are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond HTA's control. Although HTA believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, HTA's actual results and performance could differ materially and in adverse ways from those set forth in the forward-looking statements. Factors which could have a material adverse effect on HTA's operations and future prospects include, but are not limited to:

  • changes in economic conditions affecting the healthcare property sector, the commercial real estate market and the credit market;
  • competition for acquisition of medical office buildings and other facilities that serve the healthcare industry;
  • economic fluctuations in certain states in which HTA's property investments are geographically concentrated;
  • retention of HTA's senior management team;
  • financial stability and solvency of HTA's tenants;
  • supply and demand for operating properties in the market areas in which HTA operates;
  • HTA's ability to acquire real properties, and to successfully operate those properties once acquired;
  • changes in property taxes;
  • legislative and regulatory changes, including changes to laws governing the taxation of REITs and changes to laws governing the healthcare industry;
  • fluctuations in reimbursements from third party payors such as Medicare and Medicaid;
  • changes in interest rates;
  • the availability of capital and financing;
  • restrictive covenants in HTA's credit facilities;
  • changes in HTA's credit ratings;
  • HTA's ability to remain qualified as a REIT;
  • changes in accounting principles generally accepted in the United States of America, policies and guidelines applicable to REITs;
  • delays in liquidating defaulted mortgage loan investments; and
  • the risk factors set forth in HTA's most recent Annual Report on Form 10-K and in HTA's most recent Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date made. Except as otherwise required by the federal securities laws, HTA undertakes no obligation to update any forward-looking statements to reflect the events or circumstances arising after the date as of which they are made. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on the forward-looking statements included in this press release or that may be made elsewhere from time to time by, or on behalf of, HTA.

Financial Contact:
Robert A. Milligan
Chief Financial Officer
Healthcare Trust of America, Inc.
480.998.3478
[email protected]

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/healthcare-trust-of-america-inc-sets-dates-to-report-2018-second-quarter-financial-results-and-host-conference-call-300679724.html

SOURCE Healthcare Trust of America, Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, Inc.,Business,Science,Financial,Asset Management,Property Management,Business,Other,
Related Sites: DMN Newswire ,   itbusinessnet.com ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Sciatica Market Research Valued 18.9 Billion US$ by 2023: A Comprehensive Sciatica Market Growth by by type, by Drug Treatment and by End User
  • Medical Sensors Market to be Worth US$18.74 Billion by 2023, Says TMR
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • Immune Advisors Publishes Peer-Reviewed Study Demonstrating Efficacy of a Probiotic and Digestive Enzymes Supplement in Protecting Against Side Effects of Cancer Chemotherapy
  • CytRx Corporation Announces Expiration of Outstanding Warrants
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines